beta-alanine has been researched along with Drug-Related Side Effects and Adverse Reactions in 10 studies
Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation." | 9.17 | Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013) |
| "Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)." | 8.89 | Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013) |
| "Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)." | 7.79 | Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013) |
| "A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation." | 5.17 | Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013) |
| "Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)." | 4.89 | Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013) |
| " Dabigatran: elderly patients with renal failure are at higher risk of bleeding." | 4.89 | [Pharmacovigilance update]. ( Livio, F, 2013) |
| "Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)." | 3.79 | Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013) |
| "Dabigatran is a new oral direct thrombin inhibitor." | 1.40 | Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. ( Engström, M; Johansson, PI; Nilsson, CU; Ostrowski, SR; Sølbeck, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H | 1 |
| McMillin, JC | 1 |
| Frankfort, BJ | 1 |
| Al-Mohtaseb, Z | 1 |
| Imamura, K | 1 |
| Yoshida, A | 1 |
| Takei, A | 1 |
| Fukuzawa, K | 1 |
| Kiuchi, K | 1 |
| Takami, K | 1 |
| Takami, M | 1 |
| Itoh, M | 1 |
| Fujiwara, R | 1 |
| Suzuki, A | 1 |
| Nakanishi, T | 1 |
| Yamashita, S | 1 |
| Matsumoto, A | 1 |
| Hirata, K | 1 |
| Haines, DE | 1 |
| Mead-Salley, M | 1 |
| Salazar, M | 1 |
| Marchlinski, FE | 1 |
| Zado, E | 1 |
| Calkins, H | 1 |
| Yarmohammadi, H | 1 |
| Nademanee, K | 1 |
| Amnueypol, M | 1 |
| Skanes, AC | 1 |
| Saklani, P | 1 |
| Steinberg, BA | 1 |
| Hasselblad, V | 1 |
| Atwater, BD | 1 |
| Bahnson, TD | 1 |
| Washam, JB | 1 |
| Alexander, JH | 1 |
| Daubert, JP | 1 |
| Piccini, JP | 1 |
| Noheria, A | 1 |
| Asirvatham, SJ | 1 |
| Sølbeck, S | 1 |
| Nilsson, CU | 1 |
| Engström, M | 1 |
| Ostrowski, SR | 1 |
| Johansson, PI | 1 |
| Liu, P | 1 |
| Wu, C | 1 |
| Song, W | 1 |
| Yu, L | 1 |
| Yang, X | 1 |
| Xiang, R | 1 |
| Wang, F | 1 |
| Yang, J | 1 |
| Kowey, PR | 1 |
| Naccarelli, GV | 1 |
| Livio, F | 1 |
| Honegger, P | 1 |
| Werffeli, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical and Imaging Biomarker Trial of Uridine for Veterans With Suicidal Ideation[NCT03265964] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-04-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for beta-alanine and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydroc | 2013 |
1 trial available for beta-alanine and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorb | 2013 |
7 other studies available for beta-alanine and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil.
Topics: Aged; Benzoates; beta-Alanine; Cataract Extraction; Corneal Diseases; Corneal Edema; Descemet Stripp | 2020 |
Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatra | 2014 |
Uridine decreases morphine-induced behavioral sensitization by decreasing dorsal striatal dopamine release possibly via agonistic effects at GABAA receptors.
Topics: Analgesics, Opioid; Animals; Animals, Inbred Strains; beta-Alanine; Bicuculline; Corpus Striatum; Di | 2014 |
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; | 2012 |
Use of aggregating cell cultures for toxicological studies.
Topics: Animals; beta-Alanine; Biotransformation; Brain; Cell Aggregation; Cell Division; Cells, Cultured; C | 1988 |